<div id="readability-page-1"><div> <div> , /PRNewswire/ -- According to MarketsandMarkets™, the High Throughput Screening Market is projected to grow from about USD 27.66 billion in 2026 to USD 45.90 billion by 2031, at a CAGR of 10.7%. Browse 250 market data Tables and 50 Figures spread through 300 Pages and in-depth TOC on 'Electrosurgery Market - Global Forecast to 2031' High Throughput Screening Market Size &amp; Forecast: <ul type="disc"> <li>Market Size Available for Years: 2025–2031</li> <li>2026 Market Size: USD 27.66 billion</li> <li>2031 Projected Market Size: USD 45.90 billion</li> <li>CAGR (2026–2031): 10.7%</li> </ul> High Throughput Screening Market Trends &amp; Insights: <ul type="disc"> <li>By offering, the products segment accounted for the largest share of ~85.0% of the market in 2025.</li> <li>By product type, the reagents, kits, and consumables segment dominated the market, with a share of ~61.0% in 2025.</li> <li>By region, North America accounted for the largest share of ~43.0% of the market in 2025.</li> </ul> Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950 The high-throughput screening (HTS) market is expected to grow steadily due to increasing drug discovery activity, rising pharmaceutical and biotechnology R&amp;D spending, and the growing need to screen large compound, gene, and cell libraries more efficiently. HTS platforms are now widely used in early-stage discovery to identify promising hits, validate targets, and reduce lead identification time. The adoption of automated liquid handling systems, microplate readers, high-content imaging, label-free detection, and data analysis software has improved screening speed, reproducibility, and throughput. In addition, the growing use of cell-based assays, 3D cell models, organoids, and phenotypic screening is helping researchers generate more biologically relevant data. These factors support the broader adoption of HTS across pharmaceutical companies, biotechnology firms, CROs, academic institutes, and research laboratories. By service type, the primary screening services segment accounted for the largest share of the high-throughput screening (HTS) market in 2025. By service type, the high-throughput screening (HTS) market is divided into assay development &amp; optimization services, compound library management services, primary screening services, secondary screening &amp; hit confirmation services, hit validation &amp; characterization services, data analysis &amp; informatics services, and other services. In 2025, primary screening services held the largest share of the high-throughput screening (HTS) services market, as they form the core outsourced activity in early-stage drug discovery. These services are widely used by pharmaceutical and biotechnology companies to rapidly and cost-effectively screen large compound, gene, or cell libraries using automated platforms, microplate-based assays, and advanced detection systems. Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=134981950 By end user, the CROs &amp; CDMOs segment is estimated to register the fastest growth in the global high-throughput screening (HTS) products market during the forecast period of 2026–2031. The high-throughput screening (HTS) products market is divided into pharmaceutical &amp; biotechnology companies, CROs &amp; CDMOs, academic &amp; research institutes, and other end users. During the forecast period, CROs &amp; CDMOs are expected to grow at the fastest growth rate, supported by the rising outsourcing of early-stage drug discovery, assay development, screening, and hit identification activities. Many emerging biotechnology firms and mid-sized pharmaceutical companies prefer outsourcing HTS workflows to reduce capital expenditure and access specialized automation, compound libraries, assay platforms, and data analysis capabilities. This trend is increasing product demand among CROs, including microplate readers, liquid handling systems, assay kits, reagents, consumables, and screening software. North America accounted for the largest share of the high-throughput screening (HTS) market in 2025. The high-throughput screening (HTS) market is divided into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. In 2025, North America held the largest share of the global high-throughput screening (HTS) market, supported by strong pharmaceutical and biotechnology R&amp;D activity, advanced laboratory infrastructure, and the presence of leading life science tools companies and CROs. The US remains the major contributor due to its large base of drug discovery companies, academic research centers, government-funded laboratories, and contract research organizations. High adoption of automated liquid handling systems, microplate readers, high-content screening platforms, label-free technologies, and AI-enabled data analysis tools further strengthens the region's leadership in the HTS market. Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=134981950 Top Companies in High Throughput Screening Market: The Top Companies in High Throughput Screening Market include Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Revvity, Inc. (US), Tecan Group Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), and Corning Incorporated (US), among others. Browse Adjacent Markets: Biotechnology Market Research Reports &amp; Consulting Related Reports: Lab Automation Market - Global Forecast to 2031 Biochips Market - Global Forecast to 2030 Liquid Handling System Market - Global Forecast to 2030 Cell Based Assays Market - Global Forecast to 2030 Laboratory Equipment Services Market - Global Forecast to 2030 About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: [email protected] Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/5909825/MarketsandMarkets_Logo.jpg SOURCE MarketsandMarkets <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTIwJk5ld3NJdGVtSWQ9SU82Mzk4NyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MjAxMDE1UFJfTkVXU19VU1BSX19fX19JTzYzOTg3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTIwJk5ld3NJdGVtSWQ9SU82Mzk4NyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MjAxMDE1UFJfTkVXU19VU1BSX19fX19JTzYzOTg3"/></div> </div></div>

LABU

SBIO

The High Throughput Screening Market is projected to grow from USD 27.66 billion in 2026 to USD 45.90 billion by 2031, at a CAGR of 10.7%. Key drivers include increased drug discovery activities and rising R&D spending in pharmaceuticals and biotechnology. North America is expected to maintain the largest market share, supported by advanced laboratory infrastructure and strong R&D activity. Major companies in this sector include Thermo Fisher Scientific, Agilent Technologies, and Merck KGaA.

prnewswire

Thermo Fisher Scentific

Agilent Tech

VanEck Biotech ETF

SPDR S&P Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

10:15 ETHigh Throughput Screening Market worth $45.90 billion by 2031 | MarketsandMarkets™